Physician profile
Matthew Bautel
NPI 1245951870
$5,310.29
in general payments reported to CMS, 2019-2025
21 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $989 · 2024: $2,065 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,254 · Education: $56.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,253.93 |
| Education | $56.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.19 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $582.29 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $493.27 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $362.39 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $361.73 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $359.21 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $337.57 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $324.23 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $299.91 | 2023-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $296.03 | 2024-2025 | Loreev Xr |
| Alkermes, INC. | $292.55 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $272.36 | 2023-2025 | Azstarys |
| Lundbeck LLC | $179.99 | 2024-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $155.99 | 2024 | |
| Collegium Pharmaceutical, INC. | $67.80 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $57.50 | 2024 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $55.10 | 2024-2025 | Cobenfy |
| Indivior INC. | $51.05 | 2024 | Perseris |
| Luye Pharma (USA) LTD. | $47.90 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $46.21 | 2023-2024 | Trintellix |
| Tempus Ai, INC | $38.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bautel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.